Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07118670 · ClinicalTrials.gov registry record · Phase 4
High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes
A Phase 4 study of Proliferative Diabetic Retinopathy (PDR), sponsored by Edward Wood, MD.
- Active
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT07118670 is a Phase 4 study of Proliferative Diabetic Retinopathy (PDR) that is active but no longer recruiting, run by Edward Wood, MD. The registered enrollment target is 40 participants. The trial reports 3 study locations across 1 state.
The verdict
NCT07118670, a Phase 4 study of Proliferative Diabetic Retinopathy (PDR), is active but no longer recruiting, sponsored by Edward Wood, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this Phase 4 study is to evaluate the safety of aflibercept 8mg in patients with proliferative diabetic retinopathy without center-involved diabetic macular edema.
Conditions Studied
Interventions
- DRUG Aflibercept 8mg
Study Locations (3)
Texas
- Retina Consultants of Texas - Austin Retina Associates - Austin
- Retina Consultants of Texas - Bellaire
- Retina Consultants of Texas - San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-12-08 |
| Est. Completion | 2028-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07118670
The ClinicalTrials.gov registry entry for NCT07118670 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edward Wood, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Proliferative Diabetic Retinopathy (PDR) appearing as the primary indexed condition, and to 1 intervention - of which Aflibercept 8mg is the first listed.
NCT07118670 reports 3 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07118670 about?
NCT07118670 is a clinical study titled "High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes". The purpose of this Phase 4 study is to evaluate the safety of aflibercept 8mg in patients with proliferative diabetic retinopathy without center-involved diabetic macular edema.
What is the current status of trial NCT07118670?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2025-12-08. Estimated completion is 2028-04.
What conditions does trial NCT07118670 study?
This clinical trial studies the following conditions: Proliferative Diabetic Retinopathy (PDR).
What interventions are being tested in trial NCT07118670?
The interventions under investigation include: Aflibercept 8mg (DRUG).
Who is sponsoring clinical trial NCT07118670?
This trial is sponsored by Edward Wood, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07118670 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proliferative Diabetic Retinopathy (PDR)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.